Moderna Inc at JPMorgan Healthcare Conference Transcript
Hey, good afternoon, everyone. My name is Jess Fye. I'm the large cap biotech analyst at JPMorgan, and we're delighted to be continuing the conference today with Moderna.
Good news this year. We don't know how to switch rooms for Q&A. So Stéphane is going to give the presentation, and then we're going to go straight into Q&A after that. A couple of ways you can ask a question. There's mic runners in the room. So if you want to raise your hand, we'll try to get a mic to you or alternatively, you can submit a question electronically and I'll read it off the iPad up here.
So with that, let me pass it over to Moderna's CEO, Stéphane Bancel.
Thank you, Jess. Good afternoon, everybody, and thank you so much for joining us today. It's quite an impressive room for this presentation.
Before I start, let me remind you that we'll be making forward-looking statements, that investing in Moderna entails some
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |